BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 28736627)

  • 1. Personalized and precision medicine: integrating genomics into treatment decisions in gastrointestinal malignancies.
    Au TH; Wang K; Stenehjem D; Garrido-Laguna I
    J Gastrointest Oncol; 2017 Jun; 8(3):387-404. PubMed ID: 28736627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Application of Targeted Deep Sequencing in Metastatic Colorectal Cancer Patients: Actionable Genomic Alteration in K-MASTER Project.
    Lee Y; Lee S; Sung JS; Chung HJ; Lim AR; Kim JW; Choi YJ; Park KH; Kim YH
    Cancer Res Treat; 2021 Jan; 53(1):123-130. PubMed ID: 32810930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of tissue-agnostic approvals for patients with gastrointestinal malignancies.
    Bhamidipati D; Subbiah V
    Trends Cancer; 2023 Mar; 9(3):237-249. PubMed ID: 36494311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent Advances in Targeted Therapies for Advanced Gastrointestinal Malignancies.
    Huynh JC; Schwab E; Ji J; Kim E; Joseph A; Hendifar A; Cho M; Gong J
    Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32384640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted next generation sequencing in Chinese colorectal cancer patients guided anti-EGFR treatment and facilitated precision cancer medicine.
    Hou H; Liu D; Zhang C; Jiang Y; Lu G; Zhou N; Yang X; Zhang X; Li Z; Zhu H; Qian Z; Zhang X
    Oncotarget; 2017 Dec; 8(62):105072-105080. PubMed ID: 29285234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improving biomarker testing in advanced non-small-cell lung cancer and metastatic colorectal cancer: experience from a large community oncology network in the USA.
    Schwartzberg L; Daniel D; Vaena D; Slater D; Staszewski H; Fang B; Seneviratne L; Yu E; Price R; Szado T; Meyer CS; Shah A; Ma E
    Future Oncol; 2023 Jun; 19(20):1397-1414. PubMed ID: 37318757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Using circulating cell-free DNA to monitor personalized cancer therapy.
    Oellerich M; Schütz E; Beck J; Kanzow P; Plowman PN; Weiss GJ; Walson PD
    Crit Rev Clin Lab Sci; 2017 May; 54(3):205-218. PubMed ID: 28393575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparing GOZILA and COLOMATE: Ongoing Umbrella/Basket Trials Examining Genetic Testing in Gastrointestinal Malignancies.
    Bando H; Nakamura Y; Kotani D; Yoshino Y
    Oncology (Williston Park); 2021 Jul; 35(7):382-389. PubMed ID: 34286943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrating cfDNA liquid biopsy and organoid-based drug screening reveals PI3K signaling as a promising therapeutic target in colorectal cancer.
    Yang H; Xiao X; Zeng L; Zeng H; Zheng Y; Wang J; Li G; Dai W; He Y; Wang S; Peng J; Chen W
    J Transl Med; 2024 Feb; 22(1):132. PubMed ID: 38310289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. KRAS Testing for Anti-EGFR Therapy in Advanced Colorectal Cancer: An Evidence-Based and Economic Analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2010; 10(25):1-49. PubMed ID: 23074403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Next-Generation Sequencing of Circulating Tumor DNA Can Optimize Second-Line Treatment in RAS Wild-Type Metastatic Colorectal Cancer after Progression on anti-EGFR Therapy: Time to Rethink Our Approach.
    Mauri D; Kamposioras K; Matthaios D; Tolia M; Nixon I; Dambrosio M; Zarkavelis G; Papadimitriou K; Petricevic B; Kountourakis P; Kopecky J; Grašič Kuhar C; Popovic L; Chilingirova NP; De Mello RA; Dedić Plavetić N; Katsanos K; Mostert B; Alongi F; de Bari B; Corradini S; Kampletsas E; Gazouli I; Gkoura S; Amylidi AL; Valachis A
    Oncol Res Treat; 2022; 45(4):216-221. PubMed ID: 34999585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ProTarget: a Danish Nationwide Clinical Trial on Targeted Cancer Treatment based on genomic profiling - a national, phase 2, prospective, multi-drug, non-randomized, open-label basket trial.
    Kringelbach T; Højgaard M; Rohrberg K; Spanggaard I; Laursen BE; Ladekarl M; Haslund CA; Harsløf L; Belcaid L; Gehl J; Søndergaard L; Eefsen RL; Hansen KH; Kodahl AR; Jensen LH; Holt MI; Oellegaard TH; Yde CW; Ahlborn LB; Lassen U
    BMC Cancer; 2023 Feb; 23(1):182. PubMed ID: 36814246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Literature review Analysis of the Current State of Targeted Therapy for Gastrointestinal Cancers.
    Miao X; Jin C; Ji X; Teng Y; Liu J
    Altern Ther Health Med; 2024 Mar; ():. PubMed ID: 38551425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complementing Tissue Testing With Plasma Mutation Profiling Improves Therapeutic Decision-Making for Patients With Lung Cancer.
    Choudhury Y; Tan MH; Shi JL; Tee A; Ngeow KC; Poh J; Goh RR; Mong J
    Front Med (Lausanne); 2022; 9():758464. PubMed ID: 35223889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers Part 1: GI carcinomas.
    Neuzillet C; Rousseau B; Kocher H; Bourget P; Tournigand C
    Pharmacol Ther; 2017 Jun; 174():145-172. PubMed ID: 28223233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular targets in GI malignancies - A pathologist's perspective.
    Pawar S; Sharma A
    Indian J Pathol Microbiol; 2021 Jun; 64(Supplement):S43-S51. PubMed ID: 34135137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping.
    Zugazagoitia J; Ramos I; Trigo JM; Palka M; Gómez-Rueda A; Jantus-Lewintre E; Camps C; Isla D; Iranzo P; Ponce-Aix S; García-Campelo R; Provencio M; Franco F; Bernabé R; Juan-Vidal O; Felip E; de Castro J; Sanchez-Torres JM; Faul I; Lanman RB; Garrido P; Paz-Ares L
    Ann Oncol; 2019 Feb; 30(2):290-296. PubMed ID: 30535340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of Targeted Trials and Signaling Pathway Landscape in Advanced Gastrointestinal Cancers From SCRUM-Japan GI-SCREEN: A Nationwide Genomic Profiling Program.
    Nakamura Y; Yamashita R; Okamoto W; Komatsu Y; Yuki S; Ueno M; Kato K; Taniguchi H; Kagawa Y; Denda T; Hara H; Esaki T; Moriwaki T; Sunakawa Y; Oki E; Nagashima F; Nishina T; Satoh T; Kawakami H; Yamaguchi K; Ohtsubo K; Kato T; Horita Y; Tsuji A; Yasui H; Goto M; Hamamoto Y; Wakabayashi M; Ikeno T; Shitara K; Bando H; Tsuchihara K; Miki I; Ichiki H; Ohtsu A; Yoshino T
    JCO Precis Oncol; 2023 Mar; 7():e2200653. PubMed ID: 36996376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular Profiling of Advanced Malignancies: A Community Oncology Network Experience and Review of Literature.
    Tayshetye P; Miller K; Monga D; Brem C; Silverman JF; Finley GG
    Front Med (Lausanne); 2020; 7():314. PubMed ID: 32760731
    [No Abstract]   [Full Text] [Related]  

  • 20. Therapeutic Strategies in Diseases of the Digestive Tract - 2015 and Beyond Targeted Therapies in Colon Cancer Today and Tomorrow.
    Pohl M; Schmiegel W
    Dig Dis; 2016; 34(5):574-9. PubMed ID: 27332557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.